A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

NCT07312188 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG: F182112+P
DRUG: F182112+CD38

Sponsor

Shandong New Time Pharmaceutical Co., LTD